Researchers at Zhengzhou University in China have developed a new treatment for Parkinson’s disease that works via the gut. They use modified bacterial spores to deliver protective substances to the brain. In mice with Parkinson’s, the treatment resulted in fewer movement problems and less loss of nerve cells, according to reports from October 2026.
In Plain English: The Clinical Takeaway
- Targeted Delivery: Modified bacterial spores act as carriers, protecting substances through the digestive tract before releasing them to reach the brain.
- Neuroprotection: Unlike standard medications that primarily help reduce symptoms like tremors and stiff muscles, this approach aims to protect dopamine-producing nerve cells against dying.
- Preclinical Status: The treatment has only been tested in the laboratory and in mice; it remains to be seen whether it is safe and effective in humans.
Molecular Mechanism of the Bacterial Spore Carrier
Parkinson’s disease is characterized by the gradual death of nerve cells that produce dopamine, a substance that helps regulate our movements. This leads to typical symptoms such as shaking hands, stiff muscles, slower movement, and balance problems. While the exact interaction between the gut and the brain is not yet entirely clear, researchers have long suspected that changes in the gut flora can contribute to the onset or development of Parkinson’s.
To address this, researchers at Zhengzhou University used Clostridium butyricum, a bacterium that produces butyrate in the gut. The research team modified the spores of this bacterium by adding two substances: lactoferrin, a protein that helps with transport to the brain, and liproxstatine-1, a substance that counteracts certain forms of cell damage.
These bacterial spores serve as a transport vehicle. They are resistant to stomach acid and can safely reach the intestines. There, their outer layer comes off, and the proteins from that layer form tiny particles that carry the added substances. These particles can enter the bloodstream from the intestines and subsequently pass the blood-brain barrier. Once the substances reach the brain, they protect nerve cells against damage from oxidative stress, which can lead to the death of dopamine-producing nerve cells.
Preclinical Efficacy Versus Standard Pharmacotherapy
When evaluated in mice with Parkinson’s, the results were promising: the treated mice moved better and had less difficulty coordinating their movements than animals that received no treatment. They performed about as well as mice that received levodopa, a commonly used medication for Parkinson’s. However, there was a notable difference: the new treatment protected the dopamine-producing nerve cells better against dying than levodopa.
Standard medications for Parkinson’s help primarily to reduce symptoms such as tremors and stiff muscles, but they cannot stop the loss of nerve cells. The new treatment might be able to act on the disease process itself, although this has so far only been investigated in mice.
| Treatment Parameter | Standard Levodopa Therapy | Investigational Spore Delivery System |
|---|---|---|
| Primary Mechanism | Dopamine replacement | Transport of protective substances via spores |
| Symptomatic Relief | Reduces tremors and stiff muscles | Improved movement and coordination in mice |
| Disease Modification | Does not stop cell loss | Reduced neuronal cell death in mice |
| Administration Route | Standard medication | Oral ingestion (preclinical) |
When can the treatment be used in humans?
For now, the treatment has only been tested in the laboratory and in mice. Whether it works in humans and is safe remains to be seen. Moreover, everyone has a different gut flora, which means the treatment might not have the same effect in all patients. The researchers are hopeful that their approach could make it easier in the future to deliver medicines to the brain via the gut, allowing patients to take them orally without injections or other invasive procedures. However, much more research is needed before that happens.
Future Translation
A primary variable influencing future translation is that everyone has a different gut flora, which could cause the treatment to have different effects in different patients.
Keep reading
- France Launches 2023-2027 Global Health Strategy with WHO
- South Korea launches AI National Health Assistant Chatbot for public health data
- NTNU Researchers: JAK Inhibitors May Increase Viral Susceptibility (world-today-news.com)
- University of Utah Study Shows How MCT1 Fuels Heart Muscle Cells (time.news)
